Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jayant S Sanghvi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE19-08-2015
19-08-2015
Sun Pharma gains 2% after BofA-ML upgrade
The global investment bank raised the target price to Rs 1070 for Sun Pharma shares from Rs 960 earlier.19-08-2015
Sun Pharma up 4% as Ambit upbeat on new drug
Sun Pharmaceutical Industries gained 4.06 per cent in trade on Friday, heading for a fourth day of gains.14-08-2015
Results Press Release
Sun Pharmaceutical Industries Ltd has submitted to BSE a copy of Results Press Release for the period ended June 30, 2015.11-08-2015
Sun Pharma sales miss estimates amid regulatory pressures
Sales at Sun Pharma rose 3% to Rs6,520 crore in the three months ended June from Rs6,310 crore a year earlier11-08-2015
Announces Revised Annual Accounts for the year ended March 31, 2015
Sun Pharmaceutical Industries Ltd has announced the following results for the quarter & year ended March 31, 2015:The Unaudited results for the Quarter ended March 31, 2015The Company posted a net loss of Rs. (793.80) million for the Quarter ended March 31, 2015 where as the same was at net profit of Rs. 1629.60 million for the Quarter ended March 31, 2014. Total Income is Rs. 19586.20 million for the Quarter ended March 31, 2015...11-08-2015
Outcome of Board Meeting
Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 11, 2015, has recorded the approval of the Scheme of Amalgamation of Sun Pharma Global Inc., wholly-owned subsidiary of the Company, into Sun Pharmaceutical Industries Limited (SPIL) with effect from the appointed date of January 01, 2015 as per the order of the Honble High Court of Gujarat, at Ahmedabad at its hearing held...11-08-2015
Announces Q1 results & Limited Review Report for the Quarter ended June 30, 2015
Sun Pharmaceutical Industries Ltd has announced the following results for the quarter ended June 30, 2015 The Unaudited Standalone results for the Quarter ended June 30, 2015:The Company has posted a net loss of Rs. (3871.00) million for the quarter ended June 30, 2015 as compared to net profit of Rs. 8026.80 million for the quarter ended June 30, 2014. Total Income has decreased from Rs. 28989.90 million for the quarter ended June...11-08-2015
Board recommends Dividend
Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 11, 2015, inter alia, has recommended payment of dividend of Rs. 3 (Rupees Three Only) per equity share of Re. 1/- each of the Company for the year ended March 31, 2015, subject to the approval of the members at the ensuing Annual General Meeting of the Company to be held in around end of October 2015.11-08-2015
Board to Consider Revised Audited Annual Accounts for the Year ended March 31, 2015 & Dividend on August 11, 2015
With reference to the earlier letter dated July 28, 2015 regarding Q1 results on August 11, 2015, Sun Pharmaceutical Industries Ltd has now informed BSE that the Board of Directors of the Company at its meeting scheduled to be held on August 11, 201 5 would also transact the following business:1. Consideration of the revised audited annual accounts of the Company for the year ended March 31, 2015 after giving the effect to the Scheme of Amalgamation...03-08-2015